Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
Biohaven looks to have timed its exit well, giving investors more reason to cheer the $11.6bn buyout.
Deal making in biosimilars dominates a slow start to the year for biopharma M&A.
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
There are long shots and then there is troriluzole. Biohaven will soon find out if it was wise to press on with the asset.
Three of the top five buyouts of 2021 happened in the final quarter, and with biotech stocks hurting many hope that the flurry will continue.
Lilly pips Pfizer to the big pharma top spot on share price performance, while Covid-19 drives the largest risers elsewhere.